On May 4, Bioline RX Ltd (NASDAQ:BLRX) announced the expansion stage of the Phase 2 clinical trial for BL-8040, a drug for acute myeloid …
As the biotech sector becomes more volatile, analyst Joseph Pantginis of Roth Capital points out that it is increasingly necessary to “focus on names with …
